[{"orgOrder":0,"company":"RHODES PHARMACEUTICALS LP","sponsor":"Purdue Pharmaceuticals L.P","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"RHODES PHARMACEUTICALS LP","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RHODES PHARMACEUTICALS LP \/ Purdue Pharmaceuticals L.P","highestDevelopmentStatusID":"10","companyTruncated":"RHODES PHARMACEUTICALS LP \/ Purdue Pharmaceuticals L.P"},{"orgOrder":0,"company":"RHODES PHARMACEUTICALS LP","sponsor":"Purdue Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"RHODES PHARMACEUTICALS LP","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RHODES PHARMACEUTICALS LP \/ Purdue Pharma","highestDevelopmentStatusID":"10","companyTruncated":"RHODES PHARMACEUTICALS LP \/ Purdue Pharma"},{"orgOrder":0,"company":"RHODES PHARMACEUTICALS LP","sponsor":"Purdue Pharmaceuticals L.P","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"RHODES PHARMACEUTICALS LP","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RHODES PHARMACEUTICALS LP \/ Purdue Pharmaceuticals L.P","highestDevelopmentStatusID":"10","companyTruncated":"RHODES PHARMACEUTICALS LP \/ Purdue Pharmaceuticals L.P"},{"orgOrder":0,"company":"RHODES PHARMACEUTICALS LP","sponsor":"Purdue Pharmaceuticals L.P","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"RHODES PHARMACEUTICALS LP","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RHODES PHARMACEUTICALS LP \/ Purdue Pharmaceuticals L.P","highestDevelopmentStatusID":"10","companyTruncated":"RHODES PHARMACEUTICALS LP \/ Purdue Pharmaceuticals L.P"},{"orgOrder":0,"company":"RHODES PHARMACEUTICALS LP","sponsor":"Purdue Pharmaceuticals L.P","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"RHODES PHARMACEUTICALS LP","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RHODES PHARMACEUTICALS LP \/ Purdue Pharmaceuticals L.P","highestDevelopmentStatusID":"10","companyTruncated":"RHODES PHARMACEUTICALS LP \/ Purdue Pharmaceuticals L.P"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2017","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Purdue Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Purdue Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Purdue Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Purdue Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Orient Pharma","sponsor":"Durect","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"TAIWAN","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orient Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orient Pharma \/ Durect","highestDevelopmentStatusID":"10","companyTruncated":"Orient Pharma \/ Durect"},{"orgOrder":0,"company":"Orient Pharma","sponsor":"Durect","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"TAIWAN","productType":"Controlled Substance","year":"2016","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orient Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orient Pharma \/ Durect","highestDevelopmentStatusID":"10","companyTruncated":"Orient Pharma \/ Durect"},{"orgOrder":0,"company":"Bispebjerg Hospital","sponsor":"The Ministry of Science, Technology and Innovation, Denmark | Mental Health Centre Sct. Hans | University of Copenhagen | The Leiden Academic Center for Drug Research (LACDR) | Duke University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bispebjerg Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bispebjerg Hospital \/ The Ministry of Science, Technology and Innovation, Denmark | Mental Health Centre Sct. Hans | University of Copenhagen | The Leiden Academic Center for Drug Research (LACDR) | Duke University","highestDevelopmentStatusID":"11","companyTruncated":"Bispebjerg Hospital \/ The Ministry of Science, Technology and Innovation, Denmark | Mental Health Centre Sct. Hans | University of Copenhagen | The Leiden Academic Center for Drug Research (LACDR) | Duke University"},{"orgOrder":0,"company":"Bispebjerg Hospital","sponsor":"The Ministry of Science, Technology and Innovation, Denmark | Mental Health Centre Sct. Hans | University of Copenhagen | The Leiden Academic Center for Drug Research (LACDR) | Duke University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bispebjerg Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bispebjerg Hospital \/ The Ministry of Science, Technology and Innovation, Denmark | Mental Health Centre Sct. Hans | University of Copenhagen | The Leiden Academic Center for Drug Research (LACDR) | Duke University","highestDevelopmentStatusID":"11","companyTruncated":"Bispebjerg Hospital \/ The Ministry of Science, Technology and Innovation, Denmark | Mental Health Centre Sct. Hans | University of Copenhagen | The Leiden Academic Center for Drug Research (LACDR) | Duke University"},{"orgOrder":0,"company":"VU University of Amsterdam","sponsor":"SHIRE PLC","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"VU University of Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VU University of Amsterdam \/ SHIRE PLC","highestDevelopmentStatusID":"11","companyTruncated":"VU University of Amsterdam \/ SHIRE PLC"},{"orgOrder":0,"company":"King's College London","sponsor":"SHIRE PLC","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"King's College London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"King's College London \/ SHIRE PLC","highestDevelopmentStatusID":"1","companyTruncated":"King's College London \/ SHIRE PLC"},{"orgOrder":0,"company":"Shalvata Mental Health Center","sponsor":"Technion \u2013 Israel Institute of Technology","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2010","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Shalvata Mental Health Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shalvata Mental Health Center \/ Technion \u2013 Israel Institute of Technology","highestDevelopmentStatusID":"1","companyTruncated":"Shalvata Mental Health Center \/ Technion \u2013 Israel Institute of Technology"},{"orgOrder":0,"company":"Shalvata Mental Health Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Shalvata Mental Health Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shalvata Mental Health Center \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Shalvata Mental Health Center \/ Undisclosed"},{"orgOrder":0,"company":"Shalvata Mental Health Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Shalvata Mental Health Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shalvata Mental Health Center \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Shalvata Mental Health Center \/ Undisclosed"},{"orgOrder":0,"company":"Ariel University","sponsor":"Maccabi Healthcare Services, Israel","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Ariel University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ariel University \/ Maccabi Healthcare Services, Israel","highestDevelopmentStatusID":"9","companyTruncated":"Ariel University \/ Maccabi Healthcare Services, Israel"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"VA New York Harbor Healthcare System | Portland VA Medical Center | Miami VA Healthcare System | VA Boston Healthcare System","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Neurology","graph2":"Phase IV","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Office of Research and Development \/ VA New York Harbor Healthcare System | Portland VA Medical Center | Miami VA Healthcare System | VA Boston Healthcare System","highestDevelopmentStatusID":"11","companyTruncated":"VA Office of Research and Development \/ VA New York Harbor Healthcare System | Portland VA Medical Center | Miami VA Healthcare System | VA Boston Healthcare System"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Ontario Mental Health Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Centre for Addiction and Mental Health \/ Ontario Mental Health Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Ontario Mental Health Foundation"},{"orgOrder":0,"company":"The Royal Ottawa Mental Health Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"The Royal Ottawa Mental Health Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Royal Ottawa Mental Health Centre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"The Royal Ottawa Mental Health Centre \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Neurology","graph2":"Undisclosed","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"University of Utah","sponsor":"McNeil Consumer Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"University of Utah","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Utah \/ McNeil Consumer Health","highestDevelopmentStatusID":"9","companyTruncated":"University of Utah \/ McNeil Consumer Health"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Purdue Pharmaceuticals L.P \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Purdue Pharmaceuticals L.P \/ Undisclosed"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Purdue Pharmaceuticals L.P \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Purdue Pharmaceuticals L.P \/ Undisclosed"},{"orgOrder":0,"company":"Neos Therapeutics","sponsor":"Aytu BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Merger","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Neos Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Neos Therapeutics \/ Aytu BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Neos Therapeutics \/ Aytu BioPharma"},{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Moksha8 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Moksha8 Pharmaceuticals \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Moksha8 Pharmaceuticals \/ Janssen Biotech"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating, Extended Release","sponsorNew":"Aytu BioPharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aytu BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"ElMindA","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2010","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ ElMindA","highestDevelopmentStatusID":"11","companyTruncated":"Massachusetts General Hospital \/ ElMindA"},{"orgOrder":0,"company":"Avekshan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Avekshan","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avekshan \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Avekshan \/ Undisclosed"},{"orgOrder":0,"company":"Akili Interactive Labs, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2016","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Akili Interactive Labs, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akili Interactive Labs, Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Akili Interactive Labs, Inc \/ Undisclosed"},{"orgOrder":0,"company":"JPM van Stralen Medicine Professional","sponsor":"Purdue Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"JPM van Stralen Medicine Professional","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"JPM van Stralen Medicine Professional \/ Purdue Pharma","highestDevelopmentStatusID":"11","companyTruncated":"JPM van Stralen Medicine Professional \/ Purdue Pharma"},{"orgOrder":0,"company":"Brainmarc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Brainmarc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brainmarc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Brainmarc \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Meridil
Details :
Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablets) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.
Details :
Methylphenidate is a Controlled Substance drug candidate, which is currently being evaluated in clinical studies for the treatment of Alzheimer Disease.
Details :
Methylphenidate is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Schizophrenia.
Details :
Methylphenidate is a Controlled Substance drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Details :
Methylphenidate is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Details :
Foquest (Methylphenidate) is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Details :
Aytu adds Neos' established, multi-brand ADHD portfolio which includes Adzenys XR-ODT and Cotempla XR-ODT, enhancing Aytu's footprint in pediatrics and expanding its presence in adjacent specialty care segments.
Details :
The strong and diverse portfolio includes: CONCERTA®, HALDOL®, HALDOL® DECANOAS, REMINYL®, SIBELIUM®, RISPERDAL®, RISPERDAL CONSTA® and TOPAMAX®.
Details :
Methylphenidate is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Details :
Methylphenidate is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Epilepsy.
Reset All
